The Korea Times close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Business
  • Tech
  • Bio
  • Companies
Finance
  • Companies
  • Economy
  • Markets
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
Entertainment
& Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
Sports
World
  • SCMP
  • Asia
Video
  • Culture
  • People
  • News
Photos
  • Photo News
  • Darkroom
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
Finance
  • Companies
  • Economy
  • Markets
Thu, May 19, 2022 | 01:58
Markets
With AstraZeneca, SK Bioscience seeking IPO jackpot
Posted : 2020-12-07 16:22
Updated : 2020-12-08 09:27
Print Preview
Font Size Up
Font Size Down
SK Bioscience's L HOUSE vaccine center located in Andong, North Gyeongsang Province / Courtesy of SK Bioscience
SK Bioscience's L HOUSE vaccine center located in Andong, North Gyeongsang Province / Courtesy of SK Bioscience

By Anna J. Park

Since a deal was reached in July for SK Bioscience to manufacture AstraZeneca's COVID-19 vaccine, the SK affiliate has already managed to produce the vaccine at its Andong L HOUSE vaccine center.

While some vials of the vaccine produced have already been exported, SK Bioscience is working on production for the domestic market after the deal inked recently between the Korean government and the U.K.-based AstraZeneca to produce 25 million doses of its COVID-19 vaccine for local distribution.

Considering that a full-on vaccination process in the country will begin as early as sometime in the first half of next year, SK Bioscience's plan to go public early next year seems "very timely" to raise its corporate value to the fullest.

SK Bioscience selected NH Investment & Securities as its main underwriter firm, while Korea Investment & Securities and Mirae Asset Daewoo are also jointly tapped to lead the IPO process.

The financial industry estimates the value of the vaccine arm of SK Chemical to be around 3 trillion won ($2.77 billion) at the minimum, yet the company's stocks have been traded at around 2.25 million won per share at local over-the-counter markets, helping the firm's market cap to reach around 13.8 trillion won, reflecting the market's fever and interest in the company's business outlook. Its parent company SK Chemical owns about 98 percent of the firm's equity.

Market watchers expect the vaccine firm's public offering will be one of the biggest IPOs of 2021, along with LG Energy Solution, Krafton, Kakao Bank and Kakao Pay. SK Biopharmaceuticals' successful IPO, which yielded a maximum of 450 percent of profits compared to the stock's initial subscription price (49,000 won), has also boosted investors' expectations and confidence in the IPO process of another bio-related SK affiliate.

What is more promising is that unlike SK Biopharmaceuticals, which hadn't started generating profits until its IPO, SK Bioscience is already making solid operating profits. Its annual revenue in 2019 stood at 183.9 billion won and operating profit at 22.8 billion won. During the first three quarters of this year, the company has garnered 158.6 billion won in revenue and 26.8 billion won in operating profit, which led market analysts to predict the firm will record its all-time high performance this year.

"SK Bioscience's year-on-year revenue from its flu vaccine tripled in the third quarter. Given that the COVID-19 vaccine CMO's revenue will start to be reflected in the company's fourth-quarter performance, the firm's fourth-quarter revenue is expected to continue," Lee Tal-mi, analyst at SK Securities, wrote in a recent research paper.

Even without passing the break-even point, SK Biopharmaceuticals' market cap has grown from 3.83 trillion won from the standpoint of the subscription price in mid-June to 13.6 trillion won as of Monday. That's why the corporate value of the vaccine arm of SK ― currently estimated to be more than 3 trillion won ― will grow fast through the successful IPO.


Emailannajpark@koreatimes.co.kr Article ListMore articles by this reporter
 
  • [INTERVIEW] Yoon's efforts to bolster Korea-US alliance will inevitably disturb China
  • Protecting Korea's semiconductor leadership
  • CJ, Ottogi uneasy about Harim's tactics to sell new cooked rice
  • Fear of deadliest famine in 1990s haunts North Korea amid national lockdown
  • Anti-LGBTQ sentiment widespread in Korea: survey
  • South Korea to join US-led Indo-Pacific economic initiative
  • [INTERVIEW] Time to go back to corporation-driven growth: economist
  • South Korea's new COVID-19 cases above 30,000 for 2nd day; Omicron transmission continues to slow
  • North Korea asks China, Russia for help amid COVID crisis: reports
  • Nuclear war danger, Russia and Ukraine
  • Le Sserafim member Kim Ga-ram's bullying allegations resurface Le Sserafim member Kim Ga-ram's bullying allegations resurface
  • 'Doctor Strange 2' tops 5 million admissions 'Doctor Strange 2' tops 5 million admissions
  • Girls' Generation to make comeback in August after five years Girls' Generation to make comeback in August after five years
  • Musical 'Beethoven' to hit stage next year Musical 'Beethoven' to hit stage next year
  • PSY's first boy group TNX makes much-anticipated debut with EP 'Way Up' PSY's first boy group TNX makes much-anticipated debut with EP 'Way Up'
DARKROOM
  • 2022 Pulitzer Prize: Bearing witness to history

    2022 Pulitzer Prize: Bearing witness to history

  • Worsening drought puts millions at risk

    Worsening drought puts millions at risk

  • Our children deserve the best

    Our children deserve the best

  • End of mask mandates

    End of mask mandates

  • Rio Carnival returns after two-year hiatus

    Rio Carnival returns after two-year hiatus

The Korea Times
CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Location
  • Media Kit
  • Contact Us
  • Products & Service
  • Subscribe
  • E-paper
  • Mobile Service
  • RSS Service
  • Content Sales
  • Policy
  • Privacy Statement
  • Terms of Service
  • 고충처리인
  • Youth Protection Policy
  • Code of Ethics
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group